Bank of America analysts upgraded Integra LifeSciences stock from a ''neutral'' rating to a 'buy'' rating, according to WKRB.
Here are four notes:
1. The company's shares traded down 0.38 percent on Mon., Sept. 21.
2. Integra LifeSciences has a 12-month low of $42.09 and a 12-month high of $68.46.
3. The stock has a 50-day moving average of $62.13 and a 200-day moving average of $60.04.
4. The market cap is $2.17 billion and P/E ratio is 53.91.